Hasil Pencarian - Gui‐Bin Qiao

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Chromatin accessibility analysis identifies the transcription factor ETV5 as a suppressor of adipose tissue macrophage activation in obesity

    Chromatin accessibility analysis identifies the transcription factor ETV5 as a suppressor of adipose tissue macrophage activation in obesity oleh Ren-Dong Hu, Wen Zhang, Liang Li, Zu-Qi Zuo, Min Ma, Jin-Fen Ma, Ting-Ting Yin, Cai-Yue Gao, Shu-Han Yang, Zhi-Bin Zhao, Zi-Jun Li, Gui-Bin Qiao, Zhe-Xiong Lian, Kun Qu

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy

    Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy oleh Ri-Xin Chen, Shui-Dan Xu, Min-Hua Deng, Shi-Hui Hao, Jie-Wei Chen, Xiao-Dan Ma, Wei-Tao Zhuang, Jing-Hua Cao, Yong-Rui Lv, Jin-Long Lin, Si-Yu Li, Gui-Bin Qiao, Dan Xie, Feng-Wei Wang

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study)

    Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study) oleh Hai-Yu Zhou, Shao-Peng Zheng, An-Lin Li, Quan-Long Gao, Qi-Yun Ou, Yong-Jian Chen, Shao-Tao Wu, Da-Gui Lin, Sheng-Bo Liu, Lu-Yu Huang, Fa-Sheng Li, Hong-Yuan Zhu, Gui-Bin Qiao, Michael Lanuti, He-Rui Yao, Yun-Fang Yu

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

    Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG... oleh Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

    Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study oleh Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

    Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma oleh Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying Cheng, Hui-Juan Wang, Chang-Li Wang, Ming-Fang Zhao, Gui-Bin Qiao, Li-Jun Peng, Lin Yang, Gong-Yan Chen, Kai-Can Cai, Xin-Hua Xu, Liang-Ming Zhang, Guo-Sheng Feng, Jing-Min Zhou, Guo-Wu Wu, Xiao-Rong Dong, Li-Feng Wang, Hong-Mei Zhang, Ya-Jie Gao, Qiu-Ying Jiang, Shun-Dong Cang, Zhi-Xiong Yang, Xia Song, Xiao-Qing Liu, Bo Zhu, Feng-Xia Chen, Chun-Hong Hu, Xi Chen, Yi-Long Wu, Qing Zhou

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

    Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention oleh Yi‐Long Wu, Shun Lu, Ying Cheng, Qing Zhou, Hai‐Yan Tu, Qing‐Hua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, Shao‐Kun Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, An‐Wen Liu, Xu‐Chao Zhang, Hui Li, Rong‐Rong Chen, Dong‐Mei Lin, Cong‐Ying Xie, Zheng‐Fei Zhu, Hui‐Ying Liang, Yong Song, Xiao‐Rong Dong, Ming‐Fang Zhao, Gui‐Bin Qiao, Jiu‐Wei Cui, Zi‐Ming Li, Zhi‐Jie Wang, Xiao‐Yuan Chen, Nong Yang, Gen Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, Jian‐Chun Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Qi‐Tao Yu, Li‐Feng Wang, Hai‐Bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui‐Juan Wang, Fang Wu, Wen‐Zhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Li Zhang, Fan Yang, Qun Wang, Dong‐Sheng Yue, Jian‐Ya Zhou, Peng Shen, Jia‐Tao Zhang, Xiao‐Long Yan, Mei‐Juan Huang, Wei‐Neng Feng, Li Li, Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: